Investing.com - Financial Markets Worldwide
Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Arvinas Inc (ARVN)

NASDAQ
Currency in USD
25.92
+1.18(+4.77%)
Closed
After Hours
25.920.00(0.00%)
ARVN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
24.7626.42
52 wk Range
21.1753.08
Key Statistics
Edit
Prev. Close
24.74
Open
25.04
Day's Range
24.76-26.42
52 wk Range
21.17-53.08
Volume
495.07K
Average Volume (3m)
575.82K
1-Year Change
-20.71%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARVN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
62.95
Upside
+142.86%
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 8
Analysts anticipate sales growth in the current year
Unlock InvestingPro

Arvinas Inc News & Analysis

Show more

Arvinas Inc Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
415
Market
United States

Arvinas Inc SWOT Analysis

Pioneering Therapies
Arvinas leads in protein degradation therapeutics, with promising candidates for breast and prostate cancer in advanced clinical trials
Strategic Alliances
Partnerships with Pfizer and Novartis provide financial support and commercial expertise, potentially accelerating market entry for key therapies
Financial Outlook
Despite ongoing losses, Arvinas maintains a strong cash position extending into 2027, with analyst price targets ranging from $48 to $90
Market Potential
Explore Arvinas' competitive edge in large oncology markets, balancing innovative treatments against established players and regulatory challenges
Read full SWOT analysis

Compare ARVN to Peers and Sector

Metrics to compare
ARVN
Peers
Sector
Relationship
P/E Ratio
−5.8x−5.9x−0.6x
PEG Ratio
−0.300.070.00
Price/Book
3.0x2.8x2.6x
Price / LTM Sales
11.1x1.9x3.2x
Upside (Analyst Target)
135.7%92.9%44.6%
Fair Value Upside
Unlock16.9%7.3%Unlock

Analysts' Recommendations

19 Buy
2 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 62.95

(+142.85% Upside)

More details

FAQ

What Is the Arvinas (ARVN) Stock Price Today?

The Arvinas stock price today is 25.92

What Stock Exchange Does Arvinas Trade On?

Arvinas is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Arvinas?

The stock symbol for Arvinas is "ARVN."

What Is the Arvinas Market Cap?

As of today, Arvinas market cap is 1.78B.

What is Arvinas Earnings Per Share?

The Arvinas EPS is -4.46.

What Is the Next Arvinas Earnings Date?

Arvinas will release its next earnings report on 02 Mar 2025.

From a Technical Analysis Perspective, Is ARVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.